AP-HM - Hôpital de la Timone
AP-HM - Hôpital de la Timone
Marseille, France4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of INBRX-109 in Conventional Chondrosarcoma | Conventional Chondrosarcoma | Active, not recruiting | Phase 2 | 2026-07-14 | NCT04950075 | |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, metastatic malignant neoplasm, neoplasm | Recruiting | Phase 3 | 2026-06-16 | NCT05208047 | |
| Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In Patients With A Large Ischemic Stroke: A Multicenter Randomized Controlled Trial (IVT-ALL-IN) | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, brain infarction, brain ischemia, cardiovascular disorder, central nervous system disorder, cerebral infarction, cerebrovascular disorder, ischemic disease, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Not yet recruiting | Phase 3 | 2026-05-22 | NCT07603440 | |
| Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 1 / Phase 2 | 2023-02-21 | NCT05280509 |